Halogen compounds having thrombopoietin receptor agonism

Inactive Publication Date: 2004-04-01
SHIONOGI & CO LTD
View PDF0 Cites 60 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

0117] In the present specification, the term "modifying platelet production" includes 1) increasing the number of platelet decreased by administrating an antitumor agent and the like, 2) maintaining the nu

Problems solved by technology

Low molecular peptides having an affinity for the thrombopoietin receptor is also known (JP98/72492A

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Halogen compounds having thrombopoietin receptor agonism
  • Halogen compounds having thrombopoietin receptor agonism
  • Halogen compounds having thrombopoietin receptor agonism

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0186] Preparation of Compound (A-1) 20

[0187] (Step 1)

[0188] To a solution of 2'-fluoro-3'-trifluoroacetophenone (1) (20.9 g) in 10% methanol-chloroform was added bromine (5.26 mL), and the reaction mixture was stirred at room temperature until a color of bromine was disappeared. The solvent was evaporated under reduced pressure and the residue was dissolved in ethanol again. To the reaction mixture was added thiourea (7.71 g) and the mixture was heated under reflux for 2 h. To the reaction mixture was added a mixture of ethyl acetate-saturated aqueous sodium bicarbonate solution, and the organic layer was dried over anhydrous magnesium sulfate, and evaporated. The residue was purified by column chromatography to give a compound (2) (19.8 g).

[0189] .sup.1H NMR (CDCl.sub.3, .delta. ppm): 8.22-8.28 (m, 1H), 7.48-7.54 (m, 1H), 7.24-7.30 (m, 1H), 7.10 (d, 1H, J=2.4 Hz), 5.14 (bs, 2H).

[0190] (Step 2)

[0191] To a solution of methyl terephthalaldehydate (25 g) and rhodanine (23.3 g) in tolu...

formulation example

Formulation Example 1

[0211] Granules are prepared using the following ingredients.

8 Ingredients The compound represented by the formula (I) 10 mg Lactose 700 mg Corn starch 274 mg HPC-L 16 mg 1000 mg

[0212] The compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve. Corn starch is made pass through a 120 mesh sieve. They are mixed by a twin shell blender. An aqueous solution of HPC-L (low mucosity hydroxypropylcellulose) is added to the mixture and the resulting mixture is kneaded, granulated (by the extrusion with pore size 0.5 to 1 mm mesh), and dried. The dried granules thus obtained are sieved by a swing sieve (12 / 60 mesh) to yield the granules.

Formulation 2

[0213] Powders for filling capsules are prepared using the following ingredients.

9 Ingredients The compound represented by the formula (I) 10 mg Lactose 79 mg Corn starch 10 mg Magnesium stearate 1 mg 100 mg

[0214] The compound represented by the formula (I) and lactose are made pass through a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Electrical inductanceaaaaaaaaaa
Frequencyaaaaaaaaaa
Login to view more

Abstract

Compounds of the general formula (III), prodrugs thereof, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: wherein R<9 >is hydrogen atom, optionally substituted lower alkyl, or the like; R<10>, R<11 >and R<12 >are each independently optionally substituted alkyl, halogen atom, or the like; R<14 >is each independently lower alkyl, halogen atom, or the like; n is an integer of 0 to 2; A<3 >is a group represented by the formula: wherein R<13 >is hydrogen atom or lower alkyl; T is oxygen atom or sulfur atom.

Description

[0001] The present invention relates to a pharmaceutical composition exhibiting thrombopoietin receptor agonism.[0002] Thrombopoietin, polypeptide cytokine composed of 332 amino acids, activates the production of platelets by stimulating the differentiation and proliferation of megakaryocytes through the receptor and is expected as a medicine for hemopathy accompanied with the unusual number of platelets, for example, thrombocytopenia. DNA sequences encoding the thrombopoietin receptor have been described in Proc. Natl. Acad. Sci., 89, 5640-5644 (1992). Low molecular peptides having an affinity for the thrombopoietin receptor is also known (JP98 / 72492A and WO96 / 40750), but these peptide derivatives are not generally practical for oral administration.[0003] 1,4-Benzodiazepine derivatives as a low molecule compound having an affinity to the thrombopoietin receptor is described in JP99 / 1477A and JP99 / 152276A.[0004] The compound having a similar structure of the present invention compou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61P7/02A61P7/04A61P43/00C07D277/46C07D417/14
CPCC07D417/14C07D277/46A61P7/00A61P7/02A61P7/04A61P43/00A61K31/426
Inventor TAKEMOTO, HIROSHITAKAYAMA, MASAMISHIOTA, TAKESHI
Owner SHIONOGI & CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap